Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. According to Fulcrum, more than 30,000 people in the US and Europe live with Facioscapulohumeral muscular dystrophy (FSHD), and about 80% of those will lose their ability to walk.
Fulcrum Therapeutics effectively leverages small molecules to restore health in severe monogenic diseases, such as FSHD and DMD, for which there are no treatments. Foresite Capital believes that Fulcrum Therapeutics is developing a rich discovery pipeline that will address areas of large unmet need, such as Parkinson’s Disease and Sickle Cell Disease.